Controlled release by permeability alteration of cationic ammonio methacrylate copolymers using ionic interactions

Drug Development and Industrial Pharmacy

Volumn 32, Issue 6, 2006, Pages 709-718

  Ravishankar, H ^a   Patil, P ^a   Samel, A ^a   Petereit, H U ^b   Lizio, R ^b  

^a Research Centre India   (India)

^b Rohm GmbH   (Germany)

Author keywords

Controlled drug release; EUDRAGIT RS; Ionic interaction; Theophylline

Indexed keywords

ACETIC ACID; ANION; CHLORIDE; CITRIC ACID; EUDRAGIT; POLYMETHACRYLIC ACID; SUCCINIC ACID; THEOPHYLLINE;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; IN VITRO STUDY;

ACRYLIC RESINS; CATIONS; CITRATES; DELAYED-ACTION PREPARATIONS; METHACRYLATES; OSMOLAR CONCENTRATION; PERMEABILITY; POLYMERS; SODIUM ACETATE; SODIUM CHLORIDE; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; THEOPHYLLINE; TIME FACTORS;

EID: 33746907878     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600637556     Document Type: Article

References (34)

1. Arkinstall, W. W. (1988) Review of the North American experience with evening administration of Uniphyl tablets, a once daily theophylline preparation, in the treatment of nocturnal asthma. Am. J. Med., 85, 60-63.
2. Beckert, T.E., Pogarell, K., Hack, I., & Petereit, H.-U. (1999) Pulsed drug release with film coating of EUDRAGIT® & Mac 226; RS30D In Proc. Int. Symp. Control. Release Bioact. Mater., 533-534.
3. Bodmeier, R., Guo, X., Sarabia, R. E., & Scullery, P. F. (1996) The influence of buffer species and strength on Diltiazem HCl release from beads coated with the aqueous cationic polymer dispersions, EUDRAGIT® RS, RL 30D. Pharm. Res., 13 (1), 52-56.
4. British Pharmacopoeia. (2002) Published by British Pharmacopoeial Commission office, Vol. 1, 1673.
5. Bryan, J. (2005) Development of drug delivery systems that match the circadian rhythm., J. Pharm., 274, 90-91.
6. Chandrasekaran, S. K., Benson, H., & Urquhart, J. (1978) Methods to achieve controlled drug delivery: The biomedical engineering approach. In Sustained and Controlled Release Drug Delivery Systems; Robinson, J. R., Ed. New York: Marcel Dekker, Inc. 557-593.
7. Chang, R. K., & Hsiao, C. (1989) EUDRAGIT® RL and RS pseudolatices: properties and performance in pharmaceutical coating as a controlled release membrane for Theophylline pellets. Drug Dev. Ind. Pharm., 15 (2), 187-196.
8. Chidambaram, N., Porter, W., Flood, K., & Qiu, Y. (1998) Formulation and charachterization of new layered diffusion metrices for zero-order sustained-release. J. Control. Release, 52, 149-158.
9. Conte, U., & Maggi, M. (2000) A flexible technology for the linear, pulsatile and delayed release of drugs, allowing for easy accommodation of difficult in vitro targets. J. Control. Release, 64, 263-268.
10. Cortese, R., Theeuwes, F. (1982) Osmotic device with hydrogel driving member. U. S. Patent 4,327,725, May 4, 1982.
11. Gillian, C. A., & Wan, P. A. L. (1991) Factors affecting drug release from a pellet system coated with an aqueous colloidal dispersion. Int. J. Pharm., 73, 51-68.
12. Lee, L. (1992) Diffusion-controlled Matrix systems. In Treatise on controlled drug delivery; Kydonicus, A., Ed. New York: Marcel Dekker Inc. 115-198.
13. Lee, P. I. (1985) Kinetics of drug release from the hydrogel metrices. J. Control. Release, 2, 277-288.
14. Lu, E., Jiang, Z., Zhang, Q., & Jiang, X. (2003) A water-insoluble drug monolithic osmotic tablet system utilizing gum arabic as an osmotic, suspending and expanding agent. J. Control. Release, 92, 375-382.
15. Maggi, L., Shepard, T., Rochdi, M., Grenier, P., Halbeisen, S., Zimmer, R., & Conte, U. (1997) A simulation approach for effective development of a naproxen Geomatrix Quick/Slow formulation. Proc. Of the 24th Int. Symp. Control. Release Bioact. Mater. Stockholm, Sweden, June 15-19, 1997, 327-328.
16. Narasimhan, B., & Langer, R. (1997) Zero-order release of micro and macromolecules from polymeric devices: the role of the burst effect. J. Control. Release, 47, 13-20.
17. Narisawa, S., Nagata, M., Danyoshi, C., Yoshino, H., Murata, K., Hirakawa, Y., & Noda, K. (1994) An organic acid-induced sigmoidal release system for oral controlled release preparations. Pharm. Res., 11(1), 111-116.
18. Narisawa, S., Nagata, M., Hirakawa, Y., Kobayashi, M., & Yoshino, H. (1996) An organic acid- induced sigmoidal release system for oral controlled release preparations permeability enhancement of EUDRAGIT® RS coating led by the physicochemical interactions with organic acid. J. Pharm. Sci., 85 (2), 184-188.
19. Narisawa, S., Nagata, M., Ito, T., Yoshino, H., Hirakawa, Y., & Noda, K. (1995) Drug release behaviour in gastrointestinal tract of beagle dogs from multiple unit type rate controlled or time controlled release preparations coated with insoluble polymer based films. J. Control. Release, 33, 253-260.
20. Okar, R. S. (1982) Effect of polymer cation content on certain film properties. J. Pharm. Pharmacol., 34, 88-92.
21. Peppas, N. A. (1998) Hydrogels in Medicine and Pharmacy. Vols I, II and III. Boca Raton, FL: CRC Press.
22. Peppas, N. A., & Sahlin, J. J. (1989) A simple equation for the description of the solute release: III. Coupling of diffusion and relaxation. Int. J. Pharm., 57, 169-172.
23. Petereit, H.-U., Assmus, M., & Lehman, K. (1995) Glycerol Monostearate as a glidant in aqueous film-coating formulations. Eur. J. Pharm. & Biopharm., 41 (4), 219-228.
24. Petereit, H. U., Beckert, T., & Lynenskjolt, E. (2000) Coated medicament forms with controlled active substance release. W O Patent 0019984, April 13, 2000.
25. Ravishankar, H., & Renner, G. (2005) In-vivo evaluation of EUDRAMODETM: A novel diffusion controlled multiple unit drug delivery system. Transactions of 32nd Annual Meeting and Exposition of Controlled Release Society, Miami, FL, June 18-22, 2005, 161.
26. Santus, G., & Baker, R. W. (1995) Osmotic drug delivery: A review of the patent literature. J. Control. Release, 35, 1-21.
27. Smith, D. H., Neutel, J. M., & Weber, M. A. (2001) A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am. J. Hypertens., 14, 14-19.
28. Stephens, S. I., & Wong, P. S. L. (1989) Dosage form with improved delivery capability, U. S. Patent 4,863,456, September 5, 1989.
29. Talukder, R., & Fassihi, R. (2004) Gastroretentive Delivery systems: A mini review. Drug Dev. Ind. Pharm., 30 (10), 1019-1028.
30. Theeuwes, F. (1978) Osmotic system for the controlled and delivery of agent over time. U. S. Patent 4,111,202, September 5, 1978.
31. Verma, R. K., Krishna, D. M., & Garg, S. (2002) Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Control. Release, 79, 7-27.
32. Verma, R. K., Mishra, B., & Garg, S. (2000) Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm., 26 (7), 695-708.
33. Wagner K. G., & McGinity J. W. (2002) Influence of chloride ion exchange on the permeability and drug release of EUDRAGIT® RS30D films. J. Control. Release, 82 (2), 385-397.
34. Youan, B. (2004) Chronotherapeutics: gimmick or clinically relevant approach to drug delivery? J. Control. Release, 98, 337-353.